Abstract:Glycogen synthase kinase-3 (GSK-3) was discovered to be a multifunctional enzyme involved in a wide variety of biological processes, including early embryo formation, oncogenesis, as well cell death in neurodegenerative diseases. Several critical cellular processes in the brain are regulated by the GSK-3β, serving as a central switch in the signaling pathways. Dysregulation of GSK-3β kinase has been reported in diabetes, cancer, Alzheimer's disease, schizophrenia, bipolar disorder, inflammation, and Huntington's disease. Thus, GSK-3β is widely regarded as a promising target for therapeutic use. The current review article focuses mainly on Alzheimer's disease, an age-related neurodegenerative brain disorder. GSK-3β activation increases amyloid-beta (Aβ) and the development of neurofibrillary tangles that are involved in the disruption of material transport between axons and dendrites. The drug-binding cavities of GSK-3β are explored, and different existing classes of GSK-3β inhibitors are explained in this review. Non-ATP competitive inhibitors, such as allosteric inhibitors, can reduce the side effects compared to ATP-competitive inhibitors. Whereas ATP-competitive inhibitors produce disarrangement of the cytoskeleton, neurofibrillary tangles formation, and lead to the death of neurons, etc. This could be because they are binding to a site separate from ATP. Owing to their interaction in particular and special binding sites, allosteric ligands interact with substrates more selectively, which will be beneficial in resolving drug-induced resistance and also helpful in reducing side effects. Hence, in this review, we focussed on the allosteric GSK-3β inhibitors and discussed their futuristic opportunities as anti-Alzheimer's compounds.

Targeting glycogen synthase kinase-3 β for Alzheimer's disease: Recent advances and future Prospects

Targeting Glycogen Synthase Kinase-3Β for Alzheimer's Disease: Recent Advances and Future Prospects

Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease

GSK3: A potential target and pending issues for treatment of Alzheimer's disease

Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer's Disease Treatment

Targeting protein kinases for the treatment of Alzheimer's disease: Recent progress and future perspectives

Discovery of Novel Α‐carboline Derivatives As Glycogen Synthase Kinase‐3β Inhibitors for the Treatment of Alzheimer's Disease

Design, synthesis, and biological evaluation of tetrahydropyrimidine analogue as GSK-3β/Aβ aggregation inhibitor and anti-Alzheimer's agent

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer's Disease

Natural compounds from herbs and nutraceuticals as glycogen synthase kinase-3β inhibitors in Alzheimer's disease treatment

Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer's therapy

Design, Bio‐evaluation and Molecular Dynamics Simulation of Novel GSK‐3β Inhibitors

Design, synthesis and bioevaluation of 1,2,4-thiadiazolidine-3,5-dione derivatives as potential GSK-3β inhibitors for the treatment of Alzheimer's disease

Synthesis and Evaluation of Novel GSK-3β Inhibitors As Multifunctional Agents Against Alzheimer's Disease

GSK-3 in Neurodegenerative Diseases

Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents

An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease

Dual-target inhibitors of cholinesterase and GSK-3β to modulate Alzheimer's disease

Could protein phosphatase 2A and glycogen synthase kinase-3 beta be targeted by natural compounds to ameliorate Alzheimer's pathologies?

β-Amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3